Paraneoplastic Syndromes, the FDG-PET Tumor Search¹⁸F-FDG

Quick Answer

Paraneoplastic syndromes are remote, immune-mediated effects of a cancer — most consequentially the paraneoplastic neurologic syndromes (limbic encephalitis, cerebellar degeneration, encephalomyelitis, Lambert-Eaton, opsoclonus-myoclonus) driven by onconeural antibodies (anti-Hu, anti-Yo, anti-CV2, anti-Ma2, anti-amphiphysin, etc.). The neurologic syndrome and antibody frequently precede any clinically evident tumor, so whole-body FDG-PET/CT is used to hunt the occult primary — classically small-cell lung cancer, but also thymoma, breast, ovarian/teratoma, testicular, and lymphoma, guided by the specific antibody. FDG-PET adds value when conventional CT is negative and can raise the diagnostic yield enough to change management; a negative scan does not fully exclude a tiny tumor, so antibody-directed targeted imaging and interval re-screening remain part of the workup.

The clinical trigger

Suspect a paraneoplastic process when a subacute neurologic syndrome appears without another cause, especially with a positive onconeural antibody. The antibody narrows the search: anti-Hu and Lambert-Eaton (VGCC) → small-cell lung cancer; anti-Yo / anti-Ri → breast and gynecologic; anti-Ma2 → testicular germ-cell; opsoclonus-myoclonus → neuroblastoma (children) or lung/breast (adults). Because the tumor is often occult and small, metabolic whole-body imaging is the search tool when anatomic imaging is unrevealing.

Where FDG-PET fits

Whole-body FDG-PET/CT is indicated after a negative or equivocal conventional CT, to detect a hypermetabolic primary or nodal disease too small or subtle to call on CT. It is particularly useful for mediastinal/hilar small-cell disease, thymoma, and nodal/marrow lymphoma. Use the antibody to prioritize regions (e.g. testicular ultrasound and dedicated pelvic imaging for anti-Ma2, mammography/MRI for anti-Yo). Interpret against the usual inflammatory and physiologic false positives, and remember that immune infiltration itself (e.g. limbic encephalitis) can alter brain FDG metabolism (mesiotemporal hyper- or hypometabolism).

When the hunt is negative

A negative FDG-PET does not exclude a small or slow-growing tumor. Guidelines advise repeat screening at intervals (commonly every ~4–6 months for up to ~2 years) in antibody-positive patients, plus antibody-specific targeted tests (testicular ultrasound, breast MRI). The pretest logic matters: a high-specificity onconeural antibody justifies persistent searching even through initial negatives.

High-Yield Pearls

• The neurologic syndrome and onconeural antibody often precede a detectable tumor — imaging goes hunting.
• Whole-body FDG-PET/CT is the search tool when CT is negative; top targets are SCLC, thymoma, breast, ovarian/teratoma, testicular, lymphoma.
• Antibody guides the target: anti-Hu/LEMS → SCLC; anti-Yo/Ri → breast/gyn; anti-Ma2 → testis.
• A negative scan doesn't exclude tumor — re-screen at intervals and use antibody-directed tests.

Common Pitfalls

• Stopping the search after one negative PET in a strongly antibody-positive patient.
• Ignoring the antibody and not directing dedicated imaging (e.g. missing a small testicular tumor with anti-Ma2).
• Misreading inflammatory/physiologic FDG foci as the primary without correlation.

Related Pages

• Pitfalls: Physiologic FDG mimics; entities: Lung cancer, Thymic epithelial tumors.

Self-Check

Key References

• EFNS/EAN and society guidelines on screening for tumors in paraneoplastic neurologic syndromes (including FDG-PET and interval re-screening).
• Reviews of onconeural antibodies and their associated malignancies; FDG-PET yield for occult primary detection.